ISTH 2025 for Cardiac Surgery: LEX-211 (FARES-II) Trial Shows Promising Results
The International Society on Thrombosis and Haemostasis (ISTH) shared a post on X:
”New science from ISTH 2025! Watch this expert interview to learn about groundbreaking findings from the LEX-211 (FARES-II) trial on cardiac surgery.
Key takeaways:
- Superior efficacy
- Reduced transfusions
- Fewer serious adverse events”
To watch the full interview, follow the link.
Big news for cardiac surgery is coming from ISTH!
New data presented at ISTH 2025 from the LEX-211 (FARES-II) trial highlight significant advances in hemostatic management during cardiac surgery.
The trial demonstrated superior efficacy of LEX-211, with reduced transfusion requirements and fewer serious adverse events compared to standard care.
These findings mark a potential breakthrough in improving perioperative outcomes and patient safety in cardiac surgery.
Stay updated on the World of Thrombosis and Bleeding with Hemostasis Today.
-
Nov 16, 2025, 19:46Ayodeji Olayanju: Academics Blood Matter Too!
-
Nov 16, 2025, 19:30Thomas Reiser Congratulates Saskia Middeldorp on Delivering the 2025 Sol Sherry Distinguished Lecture in Thrombosis
-
Nov 15, 2025, 15:47Shannon Farmer: Congratulations to Susan Goobie and Colleagues on Publication of Their Important Study
-
Nov 15, 2025, 15:46Fotios Barkas: Explore the Latest Articles From the Journal of Atherosclerosis Prevention and Treatment!
-
Nov 15, 2025, 15:45Ludovic Helfgott: Researchers Have Analysed Novo Nordisk Product Data in Obesity and Cardiovascular Disease
-
Nov 15, 2025, 15:42Haroun Gajraj Thanks Enric Roche for Demonstrating the Piston Effect
-
Nov 15, 2025, 15:41Thrombectomy Rates Rise 700% Nationwide
-
Nov 15, 2025, 15:41Emmanuel J. Favaloro: Transitioning Patients from DOACs to Heparin
-
Nov 15, 2025, 15:40Bruno Lima: I Owe a Lot of My Career to Dr. Brad Maron